Decibel Therapeutics (DBTX) Stock Price, News & Analysis

Company Overview

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Key Stats

• Today's Range: $4.90 to $5.11
• 50-Day Range: $4.91 to $5.23
• 52-Week Range: $1.61 to $5.40
• Volume: 1.26 million shs
• Average Volume: 122,002 shs
• Market Capitalization: $123.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DBTX Stock Analysis - Frequently Asked Questions

How were Decibel Therapeutics' earnings last quarter?

Decibel Therapeutics, Inc. (NASDAQ:DBTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.23.

When did Decibel Therapeutics IPO?

Decibel Therapeutics (DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays acted as the underwriters for the IPO.

What other stocks do shareholders of Decibel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Decibel Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Wells Fargo & Company (WFC), Bank of America (BAC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DBTX
• CUSIP: N/A
• CIK: 1656536
• Web: decibeltx.com
• Phone: 617-370-8701
• Fax: N/A
• Employees: 68
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-63,010,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.03%
• Return on Assets: -53.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 3.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.28 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 25,130,000
• Free Float: 16,182,000
• Market Cap: $123.39 million
• Optionable: Not Optionable
• Beta: -0.43